These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 30452792)

  • 1. Wild-type LRRK2 as a new potential therapeutic target in idiopathic Parkinson's disease.
    Sanjari Moghaddam H; Aarabi MH
    Mov Disord; 2018 Dec; 33(12):1876. PubMed ID: 30452792
    [No Abstract]   [Full Text] [Related]  

  • 2. LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease.
    Hu D; Niu JY; Xiong J; Nie SK; Zeng F; Zhang ZH
    Curr Med Sci; 2018 Dec; 38(6):1012-1017. PubMed ID: 30536063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LRRK2 mutations in Basque patients with Parkinson's disease.
    Zarranz JJ; Gómez-Esteban JC
    Lancet Neurol; 2008 Oct; 7(10):866-7; author reply 867. PubMed ID: 18848304
    [No Abstract]   [Full Text] [Related]  

  • 4. LRRK2 in Parkinson's disease: protein domains and functional insights.
    Mata IF; Wedemeyer WJ; Farrer MJ; Taylor JP; Gallo KA
    Trends Neurosci; 2006 May; 29(5):286-93. PubMed ID: 16616379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LRRK2 activation in idiopathic Parkinson's disease.
    Di Maio R; Hoffman EK; Rocha EM; Keeney MT; Sanders LH; De Miranda BR; Zharikov A; Van Laar A; Stepan AF; Lanz TA; Kofler JK; Burton EA; Alessi DR; Hastings TG; Greenamyre JT
    Sci Transl Med; 2018 Jul; 10(451):. PubMed ID: 30045977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers.
    Zhao Y; Perera G; Takahashi-Fujigasaki J; Mash DC; Vonsattel JPG; Uchino A; Hasegawa K; Jeremy Nichols R; Holton JL; Murayama S; Dzamko N; Halliday GM
    Brain; 2018 Feb; 141(2):486-495. PubMed ID: 29253086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compensatory Mechanisms Nine Years Before Parkinson's Disease Conversion in a LRRK2 R1441H Family.
    Sambin S; Lavisse S; Decaix C; Pyatigorskaya N; Mangone G; Valabrègue R; Arnulf I; Cormier F; Lesage S; Lehericy S; Remy P; Brice A; Corvol JC
    Mov Disord; 2022 Feb; 37(2):428-430. PubMed ID: 34668587
    [No Abstract]   [Full Text] [Related]  

  • 8. LRRK2 and the new era of Parkinson's disease research.
    The Lancet Neurology
    Lancet Neurol; 2016 Nov; 15(12):1195. PubMed ID: 27751534
    [No Abstract]   [Full Text] [Related]  

  • 9. LRRK2: bridging the gap between sporadic and hereditary Parkinson's disease.
    Elbaz A
    Lancet Neurol; 2008 Jul; 7(7):562-4. PubMed ID: 18539536
    [No Abstract]   [Full Text] [Related]  

  • 10. The G2019S LRRK2 mutation: another morbid burden for Ashkenazi Jews may provide new insights on sporadic Parkinson's disease.
    Melamed E
    Mov Disord; 2013 Dec; 28(14):1912-4. PubMed ID: 24307480
    [No Abstract]   [Full Text] [Related]  

  • 11. [Mutation in LRRK2 is associated with familial presentation of Parkinson's disease in a Chilean kindred].
    Miranda M
    Rev Med Chil; 2007 Mar; 135(3):406-7. PubMed ID: 17505590
    [No Abstract]   [Full Text] [Related]  

  • 12. LRRK2 as a therapeutic target in Parkinson's disease.
    Tan EK; Schapira AH
    Eur J Neurol; 2011 Apr; 18(4):545-6. PubMed ID: 21199179
    [No Abstract]   [Full Text] [Related]  

  • 13. Association of LRRK2 and GBA mutations in a Brazilian family with Parkinson's disease.
    Spitz M; Pereira JS; Nicareta DH; Abreu Gde M; Bastos EF; Seixas TL; Pimentel MM
    Parkinsonism Relat Disord; 2015 Jul; 21(7):825-6. PubMed ID: 25952961
    [No Abstract]   [Full Text] [Related]  

  • 14. Modeling G2019S-LRRK2 Sporadic Parkinson's Disease in 3D Midbrain Organoids.
    Kim H; Park HJ; Choi H; Chang Y; Park H; Shin J; Kim J; Lengner CJ; Lee YK; Kim J
    Stem Cell Reports; 2019 Mar; 12(3):518-531. PubMed ID: 30799274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Advance of the study on LRRK2 gene in Parkinson's disease].
    Zhang Y; Chen S
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Dec; 25(6):657-9. PubMed ID: 19065525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pathogenesis of Parkinson's disease through LRRK2 mutation].
    Ohta E; Obata F
    Seikagaku; 2014 Feb; 86(1):92-7. PubMed ID: 24693706
    [No Abstract]   [Full Text] [Related]  

  • 17. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.
    Alcalay RN; Levy OA; Waters CC; Fahn S; Ford B; Kuo SH; Mazzoni P; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Wolf P; Oliva P; Keutzer J; Marder K; Zhang X
    Brain; 2015 Sep; 138(Pt 9):2648-58. PubMed ID: 26117366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.
    Matikainen-Ankney BA; Kezunovic N; Mesias RE; Tian Y; Williams FM; Huntley GW; Benson DL
    J Neurosci; 2016 Jul; 36(27):7128-41. PubMed ID: 27383589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parkinson's disease: the LRRK2-G2019S mutation: opening a novel era in Parkinson's disease genetics.
    Bonifati V
    Eur J Hum Genet; 2006 Oct; 14(10):1061-2. PubMed ID: 16835587
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.